Loading...
Loading...
CLLS| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 5.3M |
| Gross Profit | -5.1M |
| Operating Expense | 25.7M |
| Operating I/L | -30.7M |
| Other Income/Expense | -34.8M |
| Interest Income | 1.4M |
| Pretax | -64.4M |
| Income Tax Expense | -0.7M |
| Net Income/Loss | -42.9M |
Cellectis S.A. is a clinical stage biotechnological company specializing in the development of immuno-oncology products. It focuses on gene-edited T-cells expressing chimeric antigen receptors to target and eliminate cancer cells. The company's revenue is generated through its two segments, Therapeutics and Plants, with a product portfolio including UCART19, ALLO-501, ALLO-501A, ALLO-316, UCART123, UCART22, UCARTCS1, and ALLO-715, targeting various hematologic malignancies and solid tumors. Cellectis S.A. also has strategic alliances with industry leaders, such as Allogene Therapeutics, Les Laboratoires Servier, and research collaborations with renowned institutions, driving its innovative immuno-oncology solutions.
